



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 8871

SERIAL NUMBER 10/510,531	FILING or 371(c) DATE 03/30/2005 RULE	CLASS 514	GROUP ART UNIT 4173	ATTORNEY DOCKET NO. ON/4-32419A		
APPLICANTS Paul Dent, GlenAllen, VA; Steven Grant, Richmond, VA; Geoffrey Krystal, Richmond, VA; Chunrong Yu, Richmond, VA; ** CONTINUING DATA ***** This application is a 371 of PCT/IB03/01418 04/04/2003 which claims benefit of 60/371,330 04/10/2002 ** FOREIGN APPLICATIONS ***** ** IF REQUIRED, FOREIGN FILING LICENSE GRANTED **						
Foreign Priority claimed <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No 35 USC 119(a-d) conditions met <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No Verified and <u>/MARCOS L</u> <u>SZNAIDMAN/</u> Acknowledged <u>Examiner's Signature</u>		<input type="checkbox"/> Met after Allowance <u>Initials</u>	STATE OR COUNTRY VA	SHEETS DRAWINGS 0	TOTAL CLAIMS 16	INDEPENDENT CLAIMS 2
ADDRESS NOVARTIS CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 104/3 EAST HANOVER, NJ 07936-1080 UNITED STATES						
TITLE Combination of glivec (sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol, in the treatment of cancer						
FILING FEE RECEIVED 1080	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:			<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit		